The FDA's Orphan Drug Designation is granted to drugs that are intended for the safe and effective treatment of rare diseases that affect fewer than 200,000 people in the U.S. This designation provides Bolt Biotherapeutics with certain benefits, including tax credits for clinical trials and prescription drug user fee waivers. This could potentially lead to increased revenue for the company and a positive impact on its stock price.